Adenosine

Overview

The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989.

Indication

Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.

Associated Conditions

Paroxysmal Supraventricular Tachycardia (PSVT)
Pulmonary Arterial Hypertension (PAH)
SVT
Supraventricular Tachycardia (SVT)

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Adenosine vs Diltiazem for Treatment of SVT in the ED	2025/05/28	NCT06993038	Phase 4	Recruiting	Anne E. Zepeski
Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients	2024/12/05	NCT06717685	Phase 3	Recruiting	Rashid Latif Medical College
Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses	2024/08/29	NCT06578234	Phase 4	Recruiting	Region Skane
Cardiac Outcomes With Near-Complete Estrogen Deprivation	2022/04/04	NCT05309655	Not Applicable	Recruiting	Duke University
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer	2022/02/10	NCT05234307	Phase 1	Recruiting	Dwight Owen
Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction	2021/08/20	NCT05014061	Phase 3	Withdrawn	Vastra Gotaland Region
Adrenaline for the Treatment of No-Reflow in Normotensive Patients	2021/01/07	NCT04699110	Phase 4	Completed	National Institute of Cardiovascular Diseases, Pakistan
BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.	2020/12/14	NCT04666454	Phase 4	Recruiting	Vastra Gotaland Region
New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)	2020/10/23	NCT04600115	Early Phase 1	UNKNOWN	University of Utah
The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19	2020/10/19	NCT04588441	Phase 2	Withdrawn	University of Florida

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Adenosine	Eugia US LLC	55150-193	INTRAVENOUS	90 mg in 30 mL	9/5/2023
Adenosine	Fresenius Kabi USA, LLC	63323-651	INTRAVENOUS	3 mg in 1 mL	11/20/2018
Adenosine	NorthStar Rx LLC	16714-556	INTRAVENOUS	3 mg in 1 mL	7/12/2022
ADENOSINE	HF Acquisition Co LLC, DBA HealthFirst	51662-1631	INTRAVENOUS	3 mg in 1 mL	4/28/2023
Adenosine	Meitheal Pharmaceuticals Inc.	71288-207	INTRAVENOUS	3 mg in 1 mL	4/14/2025
Adenosine	Akorn	17478-542	INTRAVENOUS	3 mg in 1 mL	1/29/2024
adenosine	Mylan Institutional LLC	67457-854	INTRAVENOUS	3 mg in 1 mL	4/20/2022
Adenosine	Gland Pharma Limited	68083-101	INTRAVENOUS	3 mg in 1 mL	12/4/2017
Adenosine	Akorn	17478-953	INTRAVENOUS	3 mg in 1 mL	10/26/2017
ADENOSINE	HF Acquisition Co LLC, DBA HealthFirst	51662-1511	INTRAVENOUS	3 mg in 1 mL	1/22/2021

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
CADEN SOLUTION FOR INJECTION 6 MG / 2 ML	Valdepharm	SIN16391P	INJECTION, SOLUTION	6 mg / 2 mL	12/1/2021
ADENOCOR INJECTION 3MG/ML	Famar Health Care Services Madrid, S.A.U., CENEXI HSC	SIN07679P	INJECTION	6.0mg/2 ml	4/5/1994

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
HEPATOSWISS FOR IV INFUSION INJ	N/A	WILCOME PHARMACEUTICAL COMPANY LIMITED	N/A	N/A	11/12/1982
HEPATOSWISS IM INJ	N/A	WILCOME PHARMACEUTICAL COMPANY LIMITED	N/A	N/A	8/13/1982

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
ADENOSCAN adenosine 30mg/10mL injection vial	53226	Sanofi-Aventis Australia Pty Ltd	Medicine	A	7/19/1996
ADENOSINE VIATRIS adenosine 6 mg/2 mL solution for injection vial	152014	Alphapharm Pty Ltd	Medicine	A	8/10/2009
ADENOSINE VIATRIS adenosine 6 mg/2 mL injection pre-filled syringe	152015	Alphapharm Pty Ltd	Medicine	A	8/10/2009
ADENOSINE BAXTER adenosine 30 mg/10 mL solution for infusion vial	285931	Baxter Healthcare Pty Ltd	Medicine	A	3/7/2018
ADSINE adenosine 6 mg/2 mL solution for injection vial	285957	Baxter Healthcare Pty Ltd	Medicine	A	3/7/2018
ADENOVIEW adenosine 30 mg/10 mL solution for injection vial	176667	Alphapharm Pty Ltd	Medicine	A	2/16/2012
ADENOVIEW adenosine 60 mg/20 mL solution for injection vial	152013	Alphapharm Pty Ltd	Medicine	A	8/10/2009
ADENOSINE JUNO adenosine 30 mg/10 mL solution for injection vial	293816	Juno Pharmaceuticals Pty Ltd	Medicine	A	7/31/2018
ORTHOPLEX ADENOSINE	20023	Bio Concepts Pty Ltd	Medicine	A	10/3/1991
ADENOCOR Adenosine 6mg/2mL injection	49439	Sanofi-Aventis Australia Pty Ltd	Medicine	A	12/19/1994

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
ADENOCARD LIQ IV 3MG/ML (PRE-FILLED SYRINGE)	fujisawa pharmaceutical co, division of fujisawa canada inc.	02031078	Liquid - Intravenous	3 MG / ML	12/31/1994
ADENOCARD LIQ IV 3MG/ML	fujisawa pharmaceutical co, division of fujisawa canada inc.	02030306	Liquid - Intravenous	3 MG / ML	12/31/1993
ADENOSINE INJECTION	fresenius kabi canada ltd	02267659	Solution - Intravenous	3 MG / ML	3/27/2007
ADENOCARD INJECTION -PRE-FILLED SYRINGE	astellas pharma canada inc	02145820	Solution - Intravenous	3 MG / ML	12/31/1994
ADENOSINE INJECTION	fresenius kabi canada ltd	02457482	Solution - Intravenous	3 MG / ML	8/17/2017
ADENOCARD - LIQ RAPID BOLUS IV 3MG/ML	astellas pharma canada inc	02139308	Solution - Intravenous	3 MG / ML	8/14/1996
ADENOSCAN - (FOR IV INFUSION ONLY)	astellas pharma canada inc	02139294	Solution - Intravenous	3 MG / ML	12/31/1995
ADENOSINE INJECTION	fresenius kabi canada ltd	02457474	Solution - Intravenous	3 MG / ML	8/17/2017
AJ-ADENOSINE	agila jamp canada inc	02402246	Solution - Intravenous	3 MG / ML	N/A
AJ-ADENOSINE	agila jamp canada inc	02410559	Solution - Intravenous	3 MG / ML	N/A

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
ADENOSINA KABI 3 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADA	Fresenius Kabi España, S.A.U.	81604	SOLUCIÓN INYECTABLE EN JERINGA PRECARGADA	Uso Hospitalario	Commercialized
ADENOSINA ACCORD 30 MG/10 ML SOLUCION PARA PERFUSION EFG	Accord Healthcare S.L.U.	81546	SOLUCIÓN PARA PERFUSIÓN	Uso Hospitalario	Commercialized
ADENOSINA ACCORD 6 MG/2 ML SOLUCION INYECTABLE EFG	Accord Healthcare S.L.U.	81545	SOLUCIÓN INYECTABLE	Uso Hospitalario	Not Commercialized
ADENOSCAN 30 mg/10 ml SOLUCION PARA PERFUSION	Sanofi Aventis S.A.	61732	SOLUCIÓN PARA PERFUSIÓN	Uso Hospitalario	Commercialized
ADENOCOR 6 mg/2 ml SOLUCION INYECTABLE	Sanofi Aventis S.A.	60375	SOLUCIÓN INYECTABLE	Uso Hospitalario	Commercialized
ADENOSINA HIKMA 6 MG/2ML SOLUCION INYECTABLE EFG	Hikma Farmaceutica (Portugal) S.A.	86371	SOLUCIÓN INYECTABLE	Uso Hospitalario	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

FDA Rejects Milestone's Cardamyst for PSVT, Citing Manufacturing Issues

5 months ago

• The FDA has rejected Milestone Pharmaceuticals' nasal spray Cardamyst for paroxysmal supraventricular tachycardia, citing chemistry, manufacturing and controls issues, causing company shares to plummet over 60%. • Cardamyst, a novel calcium channel blocker, showed promising Phase III results being "twice as effective and three times as fast as placebo" in normalizing heart rhythm for the 2 million Americans affected by PSVT. • Despite the setback, Milestone plans to request a Type A meeting with the FDA to address concerns, while continuing development of Cardamyst for atrial fibrillation in Phase II trials.

Remote Ischemic Post-Conditioning Shows Promise in Neonatal Encephalopathy Trial

10 months ago

A recent trial assessed the safety and feasibility of remote ischemic post-conditioning (RIPC) in newborns with encephalopathy.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access